Dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent.
A large trial established the favorable clinical profile of a new polymer-free biolimus-A9-eluting stent (PF-BES) with a 1-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We evaluated the real-world patterns of indications, DAPT strategies and outcomes for the PF-BES following this evidence. CHANCE is a multicenter registry including all patients who underwent percutaneous coronary intervention (PCI) with at least one PF-BES. Reasons for PF-BES PCI and planned antithrombotic regimens were collected. Primary outcomes were the 390-day Kaplan Meier estimates of a patient-oriented and a device-oriented composite endpoints (POCE: death, myocardial infarction [MI] or target vessel revascularization [TVR]; DOCE: cardiac death, target vessel-MI or ischemia-driven target lesion revascularization [ID-TLR]). Between January 2016 and July 2018, 858 patients (age: 74 ±10 years, 64.6% males, 58.7% acute coronary syndrome presentation) underwent PF-BES PCI. Main reasons for PF-BES physician's choice reflected a perceived HBR in 77.7% of patients. One-month DAPT was planned in 40.3% of patients. At 390-day follow-up (median 340 days, interquartile range: 187-390 days) the incident estimate of POCE was 13.1% (any MI 3.7%, any TVR 3.4%) and of DOCE was 7.1% (TV-MI 3.6%, ID-TLR 1.4%); while 390-day estimate of any bleeding event was 11.1% (BARC 3-5 bleeding 3.0%). In a large all-comers registry, PF-BES was mostly used in HBR patients, frequently followed by very-short DAPT regimen. The reported outcomes suggest a favorable safety and efficacy profile for the PF-BES in a real-world clinical setting. (ClinicalTrials.gov identifier: NCT03622203).